IntelGenx Technologies 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Dwight Gorham

최고 경영자

US$819.6k

총 보상

CEO 급여 비율	20.2%
CEO 임기	1.3yrs
CEO 소유권	n/a
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	8.5yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Dwight Gorham 의 보수는 IntelGenx Technologies 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$820k	US$165k	-US$10m

보상 대 시장: Dwight 의 총 보상 ($USD 819.56K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 650.80K ).

보상과 수익: Dwight 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Dwight Gorham (66 yo)

1.3yrs

테뉴어

US$819,564

보상

Mr. Dwight Gorham serves as Chief Executive Officer of IntelGenx Technologies Corp. since April 13, 2023 and also serves as its Director since May 2024 and also Joined the company on April 13, 2023. He ser...

리더십 팀

이름	위치	테뉴어	보상	소유권
Dwight Gorham	CEO & Director	1.3yrs	US$819.56k	데이터 없음
André Godin	President & CFO	9yrs	US$422.32k	0.44% $ 129.2k
Tommy Kenny	Senior VP & General Counsel	3.6yrs	US$176.92k	0.13% $ 37.0k
Nadine Paiement	Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp	no data	US$163.33k	0.093% $ 27.1k
Karen Kalayajian	Vice President of Finance & Administration	1.3yrs	데이터 없음	0.16% $ 47.0k
Stephen Kilmer	Investor Relations Officer	no data	데이터 없음	데이터 없음
Ingrid Zerbe	Corporate Secretary	18.3yrs	데이터 없음	0.053% $ 15.6k
Zenoz Pourhassan	VP of Quality Operations of Subsidiary	less than a year	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

53.5yo

평균 연령

경험이 풍부한 관리: IGXT 의 관리팀은 경험 ( 2.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Dwight Gorham	CEO & Director	less than a year	US$819.56k	데이터 없음
Nadine Paiement	Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp	8.5yrs	US$163.33k	0.093% $ 27.1k
Mark Nawacki	Independent Vice Chairman	8yrs	US$83.59k	0% $ 0
Horst Zerbe	Chairman & Chairman of Scientific Advisory Board	18.3yrs	US$216.39k	0.0026% $ 758.4
Serge Gauthier	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Bernd Melchers	Independent Director	15.3yrs	US$83.59k	0.069% $ 20.0k
Barry Greenberg	Member of Scientific Advisory Board	8.5yrs	데이터 없음	데이터 없음
Ludwig Aigner	Member of Scientific Advisory Board	8.5yrs	데이터 없음	데이터 없음
Monika Trzcinska	Independent Director	2.3yrs	US$75.57k	데이터 없음

8.5yrs

평균 재임 기간

61.5yo

평균 연령

경험이 풍부한 이사회: IGXT 의 이사회는 경험(평균 재직 기간 8.5 년)으로 간주됩니다.

IntelGenx Technologies 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

IntelGenx Technologies Corp. Announces Resignation of Dwight Gorham as Chief Executive Officer

IntelGenx Technologies Corp. Announces Board Resignations

IntelGenx Technologies Corp., Annual General Meeting, May 07, 2024

IntelGenx Technologies Corp. Announces Changes to its Board of Directors

IntelGenx Technologies Corp. Announces the Resignation of J. Bernard (Bernie) Boudreau from the Board of Directors

IntelGenx Technologies Corp. Elects Monika Trzcinska As Director

Recent updates

IntelGenx Technologies Corp. Announces Resignation of Dwight Gorham as Chief Executive Officer

IntelGenx Technologies Corp. announced delayed 10-Q filing

ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp. (OTCPK:IGXT).

IntelGenx Technologies Corp. Announces Board Resignations

Intelgenx Announces First Parkinson’S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ‘Montpark’ Clinical Trial

IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA

IntelGenx Technologies Corp., Annual General Meeting, May 07, 2024

IntelGenx Technologies Corp. to Report Q4, 2023 Results on Mar 21, 2024

IntelGenx Technologies Corp. Announces Positive Results from Proof-Of-Concept Study to Assess the Palatability, Owner-Perceived Acceptability, and Ease of Repeated Administration of Intelgenx’s VetaFilm® Platform in Healthy Dogs and Cats

IntelGenx Technologies Corp. Announces Changes to its Board of Directors

IntelGenx Corp. Receives Approval to Conduct 'Montpark' Montelukast Versafilm Phase 2 Clinical Trial in Patients with Parkinson's Disease

IntelGenx Technologies Corp. to Report Q3, 2023 Results on Nov 09, 2023

Gensco® Pharma and Intelgenx Announces Rizafilm Commercialization Update in the United States

IntelGenx Corp. Provides Regulatory Update for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film

IntelGenx Technologies Corp. announced that it expects to receive CAD 9.43492 million in funding from ATAI Life Sciences AG

IntelGenx Technologies Corp. announced that it expects to receive CAD 8.42041 million in funding from ATAI Life Sciences AG

Intelgenx Technologies Corp. Completes Enrollment for `Buena' Montelukast Versafilm® Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease

IntelGenx Technologies Corp. to Report Q2, 2023 Results on Aug 14, 2023

Intelgenx Corp. Completes Enrollment for 'Buena' Montelukast Versafilm®? Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease

Intelgenx Corp. Provides Update on Research Collaboration Evaluating Montelukast Versafilm for the Treatment of Parkinson's Disease

IntelGenx Technologies Corp. Announces the Resignation of J. Bernard (Bernie) Boudreau from the Board of Directors

IntelGenx Technologies Corp. to Report Q1, 2023 Results on May 11, 2023

IntelGenx Corp. Receives FDA Pdufa Date for Rizafilm®

IntelGenx Technologies Corp. to Report Q3, 2022 Results on Nov 10, 2022

IntelGenx Files Provisional U.S. Patent Application for Advanced Oral Film Formulation Improving Cannabinoid Onset of Action

IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film

IntelGenx Corp. Submits Response to CRL from FDA for RIZAPORT VersaFilm

IntelGenx Announces Enrollment Reaches Halfway Mark in ‘BUENA’ Montelukast VersaFilm Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

IntelGenx Technologies Corp. to Report Q2, 2022 Results on Aug 11, 2022

IntelGenx Technologies Corp. Elects Monika Trzcinska As Director

IntelGenx Technologies Corp. to Report Q1, 2022 Results on May 12, 2022

First Patient Dosed in IntelGenx Technologies Corp. Resumed ‘Buena’ Montelukast Versafilm Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

IntelGenx Technologies Corp. announced that it has received $2.1 million in funding

IntelGenx Technologies Corp. to Report Q4, 2020 Results on Mar 25, 2021

IntelGenx Technologies Corp., Annual General Meeting, May 11, 2021

IntelGenx Receives USPTO Notice of Allowance for its Novel DisinteQTM-Based Disintegrating THC Oral Film

IntelGenx Files Provisional U.S. Patent Application for Novel Vetafilmtm High Loading Oral Film Platform

Intelgenx Receives First Purchase Order for Cbd Filmstrips from Heritage Cannabis

IntelGenx Corp. Announces Publication of a Study Evaluating Montelukast’s Effect on Neurological Aging

IntelGenx Technologies Corp. to Report Q3, 2020 Results on Nov 12, 2020

Heritage Cannabis Holdings Corp. Signs Letter of Intent with Intelgenx Technologies Corp. for Long-Term Cannabis Filmstrip Supply Agreement

IntelGenx Technologies Corp. announced that it has received $1.2 million in funding

IntelGenx Technologies Corp. to Report Q2, 2020 Results on Aug 13, 2020

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령